Nanox (NNOX) Q1 2026 earnings review
Guidance Scrapped, Cash Dwindles: The Hardware Reality Bites
Nanox's hardware commercialization narrative hit a major wall in Q1 2026. While total revenue grew 53% YoY to $4.3M on the back of legacy Teleradiology and AI software, the core Nanox.ARC imaging systems generated a negligible $167,000. Citing deployment and regulatory delays, management completely capitulated on its prior $35M FY26 revenue target and ceased providing forward guidance. More alarmingly, the company issued a formal 'going concern' warning as cash dropped to $44.2M against a $14M quarterly operating burn. Without an immediate capital injection, the runway is critically short.
🐂 Bull Case
Teleradiology ($3.1M) and AI/Software ($1.0M) are generating real, growing revenue, providing a foundation while hardware struggles to scale.
A Nanox.ARC system is now commercially operational and integrated into routine clinical workflow at a RadNet facility, providing a highly visible U.S. outpatient reference site.
🐻 Bear Case
With only $44.2M in cash remaining, a $14.0M quarterly operating cash burn, and a formal going concern warning, extreme shareholder dilution or unfavorable debt terms are imminent.
Despite 40 systems in 'various stages of deployment' and a massive 360-system pipeline touted last quarter, actual Q1 system revenue was just $167k, exposing a severe bottleneck in converting contracts to cash.
⚖️ Verdict: 🔴🔴
Highly Bearish. The withdrawal of the $35M guidance is a massive blow to management credibility. Coupled with a going concern warning and anemic hardware sales, the fundamental investment thesis is under severe threat.
Key Themes
Capitulation on Guidance
Reversing its narrative from just a quarter ago, Nanox withdrew its $35M revenue target for 2026 and announced it will no longer provide annual guidance. Management blamed 'longer-than-anticipated timelines' for site readiness, licensing, and partner performance. This contradicts the previously optimistic messaging around the Howard Technology and Monarch Medical partnerships, indicating that signing distributors does not smoothly translate to recognized revenue.
Going Concern Warning and Cash Burn
The company's liquidity position is decelerating rapidly. Cash and equivalents fell from $60.0M at year-end to $44.2M at the end of Q1, driven by $14.0M in negative operating cash flow. Management explicitly stated that current funds are not sufficient for the next 12 months, triggering a 'substantial doubt' going concern qualification. They are actively exploring private equity or capital market raises, which threatens severe dilution for existing shareholders.
Teleradiology Remains the Financial Anchor
Stable and accelerating slightly. Teleradiology services generated $3.1M in Q1, up from $2.6M YoY. This segment continues to support the entire enterprise, boasting a Non-GAAP gross margin of 36%. The growth was driven by customer retention, higher rates, and increased weekday scan volumes.
AI & Software Segment Boosted by Acquisition
Revenue from AI and software solutions jumped to $1.0M in Q1, up dramatically from $0.2M a year ago. This acceleration is largely attributable to $0.9M generated by the recently acquired Nanox Health IT (formerly Vaso Healthcare IT). This non-hardware revenue diversifies the top line, though it currently operates at a GAAP gross loss of $1.7M.
RadNet Commercial Activation
In a rare hardware win, a Nanox.ARC system is now fully operational and integrated into the clinical workflow at a RadNet facility. As the largest outpatient imaging center operator in the U.S., establishing RadNet as a functional reference site is critical for proving commercial viability to other networks.
South Korea Operations Pivot Widens
The operational restructuring announced last quarter (closing the Korean chip line) has escalated into a potential full exit. Nanox is now evaluating a complete sale, orderly wind-down, or broader closure of its South Korean assets. This creates uncertainty around long-term unit economics and supply chain stability for the ARC's proprietary cold-cathode X-ray tubes.
Other KPIs
The core hardware segment generated just $167,000 in revenue (two Nanox Connect units and OEM services) but cost $1.6M to produce on a Non-GAAP basis. This represents massive negative operating leverage. Until deployment volumes scale exponentially, hardware will remain a heavy drag on consolidated margins.
Accelerating significantly, up 133% YoY from $0.9M in Q1 25. This $1.3M increase was driven by salaries and marketing efforts to push U.S. commercialization. The rising cost of customer acquisition against flat hardware sales indicates poor current sales efficiency.
Guidance
Reversing entirely. Management explicitly withdrew the $35M target provided in Q3 2025. They stated that deployment variability and implementation schedules make annual guidance an inappropriate tool, signaling a total lack of near-term visibility into hardware revenue recognition.
Key Questions
Emergency Capital Terms
Given the formal going concern warning and $27M in current estimated net cash, what specific avenues of financing are being prioritized, and how does the current stock price impact your willingness to use equity vs debt?
Howard Technology Bottlenecks
You previously announced a 300-system agreement with Howard Technology Solutions. What are the exact roadblocks preventing these pre-arranged deals from turning into active, revenue-generating installations today?
South Korea Divestiture Impact
If the South Korea facility is fully sold or wound down, how does shifting entirely to outsourced partners like CSEM impact the long-term gross margin profile and intellectual property security of the Nanox.ARC tubes?